OLB) rose 11% on Tuesday after the US Food and Drug Administration granted Orphan Drug Designation to its lead candidate, POLB 001. The drug is being developed to prevent cytokine release syndrome, a severe and potentially fatal side-effect linked to some advanced cancer immunotherapies. 